Cargando…
Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX
There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal cancer; however, few studies have investigated it in pancreatic cancer. We therefore investigated whether the ETS will predict outcomes in 59 pati...
Autores principales: | Kaga, Yasuhiro, Sunakawa, Yu, Kubota, Yutaro, Tagawa, Teppei, Yamamoto, Taikan, Ikusue, Toshikazu, Uto, Yu, Miyashita, Kouichirou, Toshima, Hirokazu, Kobayashi, Kouji, Hisamatsu, Atsushi, Ichikawa, Wataru, Sekikawa, Takashi, Shimada, Ken, Sasaki, Yasutsuna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341877/ https://www.ncbi.nlm.nih.gov/pubmed/27634903 http://dx.doi.org/10.18632/oncotarget.12007 |
Ejemplares similares
-
Two cases of lymphangitic carcinomatosis as the primary symptom of colorectal carcinoma that achieved complete remission using combination anti-EGFR antibody therapy
por: Toshima, Hirokazu, et al.
Publicado: (2019) -
Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Sasaki, Yasutsuna, et al.
Publicado: (2015) -
Single-Drug Approach with Edoxaban is Effective for Resolving Non-Acute Cancer-Associated Venous Thrombosis: A Single-Arm Retrospective Analysis
por: Toshima, Hirokazu, et al.
Publicado: (2020) -
Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients
por: Shin, Dong Woo, et al.
Publicado: (2021) -
Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan
por: Takata, Kosuke, et al.
Publicado: (2016)